Tamoxifen and the risk of ovarian cancer in BRCA1 mutation carriers

Danielle Vicus, Barry Rosen, Jan Lubinski, Susan Domchek, Noah D. Kauff, Henry T. Lynch, Claudine Isaacs, Nadine Tung, Ping Sun, Steven A. Narod

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Objective: BRCA1 mutation carriers have a high rate of both breast and ovarian cancer. Tamoxifen is a selective estrogen receptor modulator (SERM), which is used for the treatment of primary breast cancer and for the prevention of contralateral breast cancer. Our objective is to assess if tamoxifen treatment is associated with an increase in the subsequent risk of ovarian cancer among women with a BRCA1 mutation. Methods: A matched case-control study was performed. Cases were 154 women with ovarian cancer and a previous history of breast cancer. Controls were 560 women with no ovarian cancer and a history of breast cancer. All cases and controls carry a deleterious BRCA1 mutation. Cases and controls were matched for year of birth, age at diagnosis of breast cancer and country of residence. The effect of tamoxifen treatment on the risk of subsequent ovarian cancer was estimated using conditional logistic regression. Results: The unadjusted odds ratio for ovarian cancer, given previous tamoxifen treatment was 0.89 (95% CI 0.54-1.49, p = 0.66). After adjusting for other treatments, the odds ratio was 0.78 (95% CI 0.46-1.33, p = 0.36). Conclusion: Tamoxifen treatment for breast cancer does not appear to increase the risk of ovarian cancer in BRCA1 mutation carriers.

Original languageEnglish
Pages (from-to)135-137
Number of pages3
JournalGynecologic Oncology
Volume115
Issue number1
DOIs
StatePublished - Oct 2009

Fingerprint

Tamoxifen
Ovarian Neoplasms
Breast Neoplasms
Mutation
Therapeutics
Odds Ratio
Selective Estrogen Receptor Modulators
Case-Control Studies
Logistic Models
Parturition

All Science Journal Classification (ASJC) codes

  • Obstetrics and Gynecology
  • Oncology

Cite this

Vicus, D., Rosen, B., Lubinski, J., Domchek, S., Kauff, N. D., Lynch, H. T., ... Narod, S. A. (2009). Tamoxifen and the risk of ovarian cancer in BRCA1 mutation carriers. Gynecologic Oncology, 115(1), 135-137. https://doi.org/10.1016/j.ygyno.2009.06.012

Tamoxifen and the risk of ovarian cancer in BRCA1 mutation carriers. / Vicus, Danielle; Rosen, Barry; Lubinski, Jan; Domchek, Susan; Kauff, Noah D.; Lynch, Henry T.; Isaacs, Claudine; Tung, Nadine; Sun, Ping; Narod, Steven A.

In: Gynecologic Oncology, Vol. 115, No. 1, 10.2009, p. 135-137.

Research output: Contribution to journalArticle

Vicus, D, Rosen, B, Lubinski, J, Domchek, S, Kauff, ND, Lynch, HT, Isaacs, C, Tung, N, Sun, P & Narod, SA 2009, 'Tamoxifen and the risk of ovarian cancer in BRCA1 mutation carriers', Gynecologic Oncology, vol. 115, no. 1, pp. 135-137. https://doi.org/10.1016/j.ygyno.2009.06.012
Vicus, Danielle ; Rosen, Barry ; Lubinski, Jan ; Domchek, Susan ; Kauff, Noah D. ; Lynch, Henry T. ; Isaacs, Claudine ; Tung, Nadine ; Sun, Ping ; Narod, Steven A. / Tamoxifen and the risk of ovarian cancer in BRCA1 mutation carriers. In: Gynecologic Oncology. 2009 ; Vol. 115, No. 1. pp. 135-137.
@article{14df275fa4c54b1abbd72292ea7a49a8,
title = "Tamoxifen and the risk of ovarian cancer in BRCA1 mutation carriers",
abstract = "Objective: BRCA1 mutation carriers have a high rate of both breast and ovarian cancer. Tamoxifen is a selective estrogen receptor modulator (SERM), which is used for the treatment of primary breast cancer and for the prevention of contralateral breast cancer. Our objective is to assess if tamoxifen treatment is associated with an increase in the subsequent risk of ovarian cancer among women with a BRCA1 mutation. Methods: A matched case-control study was performed. Cases were 154 women with ovarian cancer and a previous history of breast cancer. Controls were 560 women with no ovarian cancer and a history of breast cancer. All cases and controls carry a deleterious BRCA1 mutation. Cases and controls were matched for year of birth, age at diagnosis of breast cancer and country of residence. The effect of tamoxifen treatment on the risk of subsequent ovarian cancer was estimated using conditional logistic regression. Results: The unadjusted odds ratio for ovarian cancer, given previous tamoxifen treatment was 0.89 (95{\%} CI 0.54-1.49, p = 0.66). After adjusting for other treatments, the odds ratio was 0.78 (95{\%} CI 0.46-1.33, p = 0.36). Conclusion: Tamoxifen treatment for breast cancer does not appear to increase the risk of ovarian cancer in BRCA1 mutation carriers.",
author = "Danielle Vicus and Barry Rosen and Jan Lubinski and Susan Domchek and Kauff, {Noah D.} and Lynch, {Henry T.} and Claudine Isaacs and Nadine Tung and Ping Sun and Narod, {Steven A.}",
year = "2009",
month = "10",
doi = "10.1016/j.ygyno.2009.06.012",
language = "English",
volume = "115",
pages = "135--137",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Tamoxifen and the risk of ovarian cancer in BRCA1 mutation carriers

AU - Vicus, Danielle

AU - Rosen, Barry

AU - Lubinski, Jan

AU - Domchek, Susan

AU - Kauff, Noah D.

AU - Lynch, Henry T.

AU - Isaacs, Claudine

AU - Tung, Nadine

AU - Sun, Ping

AU - Narod, Steven A.

PY - 2009/10

Y1 - 2009/10

N2 - Objective: BRCA1 mutation carriers have a high rate of both breast and ovarian cancer. Tamoxifen is a selective estrogen receptor modulator (SERM), which is used for the treatment of primary breast cancer and for the prevention of contralateral breast cancer. Our objective is to assess if tamoxifen treatment is associated with an increase in the subsequent risk of ovarian cancer among women with a BRCA1 mutation. Methods: A matched case-control study was performed. Cases were 154 women with ovarian cancer and a previous history of breast cancer. Controls were 560 women with no ovarian cancer and a history of breast cancer. All cases and controls carry a deleterious BRCA1 mutation. Cases and controls were matched for year of birth, age at diagnosis of breast cancer and country of residence. The effect of tamoxifen treatment on the risk of subsequent ovarian cancer was estimated using conditional logistic regression. Results: The unadjusted odds ratio for ovarian cancer, given previous tamoxifen treatment was 0.89 (95% CI 0.54-1.49, p = 0.66). After adjusting for other treatments, the odds ratio was 0.78 (95% CI 0.46-1.33, p = 0.36). Conclusion: Tamoxifen treatment for breast cancer does not appear to increase the risk of ovarian cancer in BRCA1 mutation carriers.

AB - Objective: BRCA1 mutation carriers have a high rate of both breast and ovarian cancer. Tamoxifen is a selective estrogen receptor modulator (SERM), which is used for the treatment of primary breast cancer and for the prevention of contralateral breast cancer. Our objective is to assess if tamoxifen treatment is associated with an increase in the subsequent risk of ovarian cancer among women with a BRCA1 mutation. Methods: A matched case-control study was performed. Cases were 154 women with ovarian cancer and a previous history of breast cancer. Controls were 560 women with no ovarian cancer and a history of breast cancer. All cases and controls carry a deleterious BRCA1 mutation. Cases and controls were matched for year of birth, age at diagnosis of breast cancer and country of residence. The effect of tamoxifen treatment on the risk of subsequent ovarian cancer was estimated using conditional logistic regression. Results: The unadjusted odds ratio for ovarian cancer, given previous tamoxifen treatment was 0.89 (95% CI 0.54-1.49, p = 0.66). After adjusting for other treatments, the odds ratio was 0.78 (95% CI 0.46-1.33, p = 0.36). Conclusion: Tamoxifen treatment for breast cancer does not appear to increase the risk of ovarian cancer in BRCA1 mutation carriers.

UR - http://www.scopus.com/inward/record.url?scp=69249217782&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69249217782&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2009.06.012

DO - 10.1016/j.ygyno.2009.06.012

M3 - Article

VL - 115

SP - 135

EP - 137

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 1

ER -